Sector News

Horizon seals $800m Raptor buy

October 26, 2016
Life sciences

Dublin, Ireland-headquartered Horizon Pharma has now completed the acquisition of US group Raptor Pharmaceutical.

Under the deal, Horizon has acquired all of issued and outstanding shares of Raptor common stock for $9.00 per share in cash, which equates to around $800 million in total.

According to Horizon, the deal strengthens its focus on rare diseases and provides expansion into Europe and other international markets, and diversifies revenue with 11 medicines across three business units orphan, rheumatology and primary care.

“The acquisition of Raptor directly aligns with our long-term strategy and evolution into a rare disease focused company, where now more than half of our medicines are used to treat patients with rare diseases,” said Timothy P. Walbert, chairman, president and chief executive of Horizon.

“The added infrastructure in Europe and other key international markets will further benefit the access to both our current and newly acquired medicines as well as position us for the potential introduction of Actimmune for Friedreich’s ataxia in Europe in future years if the results of the Phase III trial are positive.”

The deal is expected to be accretive to adjusted EBITDA in 2017.

By Selina McKee

Source: Pharma Times

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach